Evolving Vision MeiraGTxs Gene Therapy Restores Sight for Children with LCA4,

Published | Modified February 21, 2025
CSIMarket Newsroom | CSIMarket.com

In an extraordinary breakthrough in the field of genetic medicine, MeiraGTx Holdings plc (Nasdaq: MGTX), a leading clinical-stage genetic medicines company, has announced the publication of a significant study in The Lancet that reports the efficacy of its gene therapy, rAAV8.hRKp.AIPL1, in treating children with AIPL1-associated severe retinal dystrophy, specifically Leber Congenital Amaurosis 4 (LCA4).

The paper

Sources for this article: Based on Meiragtx Holdings Plc’s official statement and CSIMarket.com Customer Analytics Research for Meiragtx Holdings Plc

For details on how CSIMarket validates financial and corporate news, please review our Editorial Standards & Fact-Checking Policy .

Comments

Comments are available to active subscribers. Subscribe or Log in.

Get the full CSIMarket dataset: Subscribe API License